News | January 24, 2026
Akums bags key EU GMP certifications for 2 Haridwar plants
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Medico Remedies receives order worth US$ 1,781,000
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
